9th Annual Biomarkers Congress

View Profile


Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors
1. 2010 Conflicts of interest, authorship and disclosures in industry-related scientific publications Mayo Clin Proc 2010;85(2):197-9; author reply 201-4, 2010 Feb.
2. 2010 Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients Blood 2010 Feb 18; 115(7):1343-50
3. 2010 Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6 Blood 115(8):1594-604, 2010 Feb 25.
4. 2010 Continuing medical education - limiting industry's influence N Engl J Med.362(11):1053; author reply 1053-4, 2010 Mar 18
5. 2009 International Myeloma Working Group molecular classification of multiple myeloma: spotlight review Leukemia 2009 Oct ; Epub
6. 2009 Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. Journal of Clinical Oncology 2009 Aug 31; Epub
7. 2009 Spontaneous remission in a patient with t(4:14) translocation multiple myeloma Journal of Clinical Oncology, 27(30):5008-14, 2009 Oct 20.
8. 2009 Gene expression profiling of pulmonary mucosa-associated lymphoid tissue lymphoma identifies new biologic insights with potential diagnostic and therapeutic applications. Blood 2009 Jan 15; 113(3):635-645
9. 2009 Centrosomes and Myeloma; aneuploidy and proliferation Environmental and Molecular Mutogenesis, 2009 Oct;50(8):697-707.
10. 2009 Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomized controlled trial Lancet Oncology 2009 Oct 21; Epub
11. 2009 Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines. Mayo Clin Proc 2009 Dec;84(12):1095-110
12. 2009 Diagnosis and Genetic Classification of Multiple Myeloma Greer, John P. (editor). Wintrobe’s Clinical Hematology, Edition 12. Lippincott Williams & Wilkins 2009.
13. 2009 Diagnosis and Genetic Classification of Multiple Myeloma Rajkumar, S. Vincent and Kyle Robert A. (editors). Treatment of Multiple Myeloma and Related Disorders. Cambridge University Press 2009.
14. 2009 Cytogenetic Abnormalities in Multiple Myeloma Lonial, Sagar (editor) Myeloma Therapy Pursuing the Plasma Cell, First Edition. Humana Press 2008
15. 2009 Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis Haematologica 2009 Mar;94(3);380-386
16. 2009 Identification of copy-number abnormalities and inactivating mutations in two negative regulators of NF-kB signaling pathways in Waldenström’s Macroglobulinemia Cancer Research 2009 Apr 15;69(8):3579-88.
17. 2009 High-resolution genomic analysis in Waldenströms Macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomas. Clin Lymphoma Myeloma, 2009 Mar;9(1):39-42.
18. 2009 Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rate in a phase II clinical trial Leukemia 2009 Jul;23(7):1337-41
19. 2009 Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone.
20. 2009 Genetic markers as prognostic factors in multiple myeloma. Revista Medica de Chile 2009 Apr;137(4):552-558
21. 2008 Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2 Blood. 112(5):1931-41, 2008 Sept 1.
22. 2008 Plasma Cell Disorders Working Committee. Comparison of twin and autologous transplants for multiple myeloma Biology of Blood and Marrow Transplantation 2008 Oct;14(10):1118-1124
23. 2008 Consolidation therapy with bortezomib/lenalidomide/dexamethasone versus bortezomib/dexamethasone after a desamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial Clinical Lymphoma and Myeloma 2008 Oct;8(5):315-317.
24. 2008 Clinical and biological significance of RAS mutations in multiple myeloma Leukemia 2008 Dec;22(12):2280-2284.
25. 2008 A novel report of cig-FISH and cytogenetics in POEMS syndrome Am J Hematol 2008 Nov; 83(11):840-1.
26. 2008 Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 2008 Jun;22(6):1282-1284
27. 2008 Association of transloction t(11;14) with survival in patients with light (AL) amyloidosis. J Clini Oncol 26:2008 (May 20 suppl;abstr 8549).
28. 2008 Impact of lenalidomide therapy on stem cell mobilization in myeloma J Clini Oncol 26:2008 (May 20 suppl;abstr 8543).
29. 2008 Efficacy of induction with cybord in newly diagnosed multiple myeloma J Clini Oncol 26:2008 (May 20 suppl;abstr 8517).
30. 2008 Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: Analysis of response, survival, and outcome J Clini Oncol 26:2008 (May 20 suppl;abstr 8504
31. 2008 Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008 Jan 15;111(2):785-789
32. 2008 AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of postgerminal center malignancies. Cancer Cell 2008 Feb.;13(2):167-180
33. 2008 Acute myocardial infarction: an unusual presentation of essential thrombocytosis in a 17-year-old man Clinical Advances in Hematology and Oncology 2008 Feb;6(2):133-141
34. 2008 The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition Blood 2008 Feb 1;111(3):1603-1609
35. 2008 Cell lines of hyperdiploid myeloma, are we there yet? British Journal of Haematology 2008 Mar;140(5):579-580
36. 2008 Effect of tissue shipping on plasma cell isolation, viability, and RNA integrity in the context of a centralized good laboratory practice-certified tissue banking facility Cancer Epidemiology, Biomarkers and Prevention 2008 Mar;17(3):666-673
37. 2008 Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature Leukemia. 22(2):459-61,2008 Feb
38. 2008 Expression and mutation status of candidate kinases in multiple myeloma Leukemia 2008 Apr;22(4):889-90.
39. 2008 Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10, 549 patients from the International Myeloma Working Group Blood 2008 Apr 15;111(8):4039-4047
40. 2008 Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity Journal of Clinical Investigation 2008 May 1;118(5):1750-1764
41. 2008 Genetic aberrations and survival in plasma cell leukemia. Leukemia 22(5):1044-52, 2008 May
42. 2008 Do beta2 microglobulin levels affect survival of newly diagnosed myeloma patients with translocation t(4;14) or 17p13 deletion treated with conventional chemotherapy? ] Leukemia 22(5):1080-1, 2008, May
43. 2008 Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) along (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group Cancer 2008 Jul 1:113(1):108-116
44. 2008 Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma
45. 2007 Dissecting Karyotypic Patterns in Non Hyperdiploid Multiple Myeloma: An Overview on the Karyotypic Evolution Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 2491
46. 2007 RB1 Haploinsufficiency Confers a Proliferation Advantage in Myeloma Cell Lines Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 2489
47. 2007 Comparative High Resolution Array-Based CGH (aCGH) in B-Cell Malignancies. Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 2479
48. 2007 14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg-FISH). Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 2477.
49. 2007 Inactivation of Tumor Necrosis Factor 3 Gene (TRAF3) Is Frequently Identified in Waldenström’s Macroglobulinemia Patients. Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 2476
50. 2007 Identification of Survival Critical Genomic Gains or Losses in Myeloma (MM) Using Array-Comparative Genomic Hybridization (aCGH) Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 2471
51. 2007 PRL3 Is a Mediator of IL6/STAT3 Signaling and Defines a Population of Multiple Myeloma Patients Distinct from Those That Activate NFkB Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 671
52. 2007 Gene Expression Profiling of Pulmonary Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Identifies New Diagnostic Markers, Biological Heterogeneity and Therapeutic Targets Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 560
53. 2007 Genome-Wide Profiling of Gene Expression and DNA Copy Number Alterations in Multiple Myeloma Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 396
54. 2007 Activation of MYC Pathway Is a Unifying Pathological Event in the Progression from Monoclonal Gammopathy of Undetermined Significance (MGUS) to Myeloma (MM). Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 241
55. 2007 A Phase II Trial of Myeloma Induction Therapy with Cyclophosphamide, Bortezomib, and Dexamethasone (Cybor-D): Improved Response over Historical Lenalidomide-Dexamethasone Controls Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 3601
56. 2007 Phase 1 Dose Escalation Study of the Monoclonal Antibody Against the Insulin Like Growth Factor I Receptor CP-751,871 in Patients with Multiple Myeloma Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 1171.
57. 2007 Phase II Trial of Lenalidomide, Cyclophosphamide, and Dexamethasone (CRd) for Newly Diagnosed Myeloma Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 190
58. 2007 A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group. Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 74
59. 2007 Immunoglobulin Free Light Chain Ratio Is an Independent Risk Factor for Progression of Smoldering Multiple Myeloma Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 1487
60. 2007 Multiple Myeloma (MM) Is Characterized by Genomic Instability Regardless of Ploidy Categories and Degree of Karyotypic Complexity Is an Important Prognostic Factor. Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 1476
61. 2007 Phase II Pilot Study of Rituximab + CHOP in Patients with Newly Diagnosed Waldenström’s Macroglobulinemia, an Eastren Cooperative Oncology Group Trial (Study E1A02). Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 3616
62. 2007 The Multiple Myeloma Research Consortium Genomics Initiative Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 2498
63. 2007 Waldenström Macroglobulinaemia: The Impact of Cytogenetic Analysis Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 2490
64. 2007 Prediction of response to bortezomib and dexamethasone resistance in myeloma (MM) by novel mutations in the NFKB pathway Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007;8007
65. 2007 Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007;LBA8025
66. 2007 Cytogenetic analysis using multiple myeloma targets in POEMS syndrome Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007;8116
67. 2007 Prognostic Factors and Staging in Multiple Myeloma Hematol Oncol Clin N Am 2007 Dec;21(6):1115-1140.
68. 2007 Strategies for risk-adapted therapy in myeloma Hematology/The Education Program of the American Society of Hematology 2007:304-310
69. 2007 Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution Leukemia 2007 Nov;21(11):2358-9
70. 2007 Transfusion-dependent anemia after initiation of androgen deprivation therapy for metastatic prostate cancer Urology 2007 Oct;70(4):811.e5-8
71. 2007 Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma Mayo Clin Proc 2007 Oct; 82(10):1179-1184.
72. 2007 Waldenstrom macroglobulinaemia British Journal of Haematology. 138(6):700-20, 2007 Sept
73. 2007 Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007 Sept; 21(9):2035-2042
74. 2007 Promiscuous Mutations Activate the Noncanonical NF-kB Pathway in Multiple Myeloma Cancer Cell 2007 Aug:12:131-144
75. 2007 Genomics and proteomics in multiple myeloma and Waldenstrom macroglobulinemia. Curr Opin Hematol 2007 July; 14(4):369-374
76. 2007 Review of molecular diagnostics in multiple myeloma Expert Review of Molecular Diagnostics 2007 Jul;7(4):453-459.
77. 2007 Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma. The New England Journal of Medicine 2007 June 21;356:2582-2590.
78. 2007 Expression and mutation status of candidate kinases in multiple myeloma. Leukemia 2007 May;21(5):1124-1127
79. 2007 Proteomic analysis of Waldenstrom macroglobulinemia. Cancer Research 2007 Apr 15;67(8):3777-3784.
80. 2007 Targeted therapeutics for multiple myeloma: the arrival of a risk-stratified approach. Molecular Cancer Therapeutics 2007 Mar;6(3)802-810
81. 2007 Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling Cancer Research 2007 Apr 1;67(7):2982-2989
82. 2007 Clinical significance of TP53 mutation in myeloma. Leukemia 2007 Mar;21(3):582-584
83. 2007 A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy Leukemia. 21(3):529-534, 2007 Mar
84. 2007 Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and risk-adapted therapy (mSMART): consensus statement. Mayo Clinic Proceedings 2007 Mar;82(3):323-341
85. 2007 Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications Blood 2007 Feb 1;109(3):1228-1232
86. 2007 6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis British Journal of Haematology 2007 Jan;136(1): 80-86
87. 2006 IGF-1R is overexpressed in poor-prognostic subtypes of multiple myeloma Leukemia 2006 Jan 20(1):174-6.
88. 2006 Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006 Jan 20;24(3):431-6.
89. 2006 Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenström macroglobulinaemia British Journal of Haematology 2006 Apr;133(2):158-164
90. 2006 Natural history of thromboembolism in AL amyloidosis Amyloid 2006 Mar; 13(1):31-36.
91. 2006 Thrombocytopenia Pp. 259-269. Mayo Clinic Medical Manual. Oliveira GH. Nesbitt GC. Murphy JG. Editors. Boca Raton: Mayo Clinic Scientific Press, Taylor and Francis Group, 2006.
92. 2006 Neutropenia Pp. 661-665. Mayo Clinic Medical Manual. Oliveira GH. Nesbitt GC. Murphy JG. Editors. Boca Raton: Mayo Clinic Scientific Press, Taylor and Francis Group, 2006.
93. 2006 Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points Haematologica 2006 Mar; 91(3):390-393
94. 2006 Promiscuous Mutations Frequently Activate the Non-Canonical NFkB Pathway in Multiple Myeloma (MM). Blood 108 (Pt 1):36a, 2006.
95. 2006 Combined High Resolution Array Comparative Genomic Hybridization and Gene Expression Profiling Reveal Rb1 Haploinsufficiency as a Possible Tumorigenic Mechanism in Myeloma Blood 108 (Pt 1):371-38a, 2006
96. 2006 Lenalidomide Plus Dexamethasone (Rev/Dex) in Newly Diagnosed Myeloma: Response to Therapy, Time to Progression, and Survival. Blood 108 (Pt 1):239a, 2006
97. 2006 A Randomized Phase III Trial of Lenalidomide Plus High-Dose Dexamethasone Versus Lenalidomide Plus Low-Dose Dexamethasone in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group. Blood 108 (Pt 1):239a-240a, 2006
98. 2006 High Resolution Array CGH Identifies TRAF3 as a Novel Tumor Suppressor in Multiple Myeloma Blood 108 (Pt 1):973a, 2006
99. 2006 Diagnostic Evaluation of t(4;14) in Multiple Myeloma Blood 108 (Pt 1):998a, 2006
100. 2006 Single Agent Bortezomib is Associated with a High Response Rate in Patients with High Risk Myeloma. A Phase II Study from the Eastern Cooperative Oncology Group (E2A02). Blood 108 (Pt 1):1006a, 2006
101. 2006 Long-Term Results of Single-Agent Thalidomide as Initial Therapy for Asymptomatic (Smoldering or Indolent) Myeloma Blood 108 (Pt 1):1019a, 2006
102. 2006 Natural History, Genetic Aberrations and Survival Distinguish Primary Plasma Cell Leukemia from Multiple Myeloma with Leukemic Transformation Blood 108 (Pt 1):1024a-1025a, 2006
103. 2006 Ploidy status rarely changes in myeloma patients at disease progression. Leuk Res 2006 Mar; 30(3):266-71
104. 2006 A phase II trial of imitanib in patients with refractory/relapsed myeloma Leuk Lympho 2006 Jan; 47(1):39-42
105. 2006 Analysis of genetic abnormalities provides insights into genetic evolution of hyperdiploid myeloma. Genes, Chromosomes and Cancer 2006 Dec; 45(12):1111-1120
106. 2006 Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia 2006 Nov;20(11):2034-2040
107. 2006 Gene-expression profiling of Waldenström macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma Blood 2006 Oct 15 108(8):2755-63
108. 2006 6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance Cancer Genetics and Cytogenetics 2006 Sep; 169(2): 150-153.
109. 2006 Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma Mayo Clin Proc 2006 Aug;81(8):1047-1053
110. 2006 Prognostic factors for hyperdiploid-myeloma; effects of chromosome 13 deletions and IgH translocations Leukemia 2006 May;20(5):807-813
111. 2006 Clinical implication of centrosome amplification in plasma cell neoplasm Blood 2006 May 1;107(9):3669-3675
112. 2005 Clinical implications of t(11;14)(q13;q32), t(4;14) (p16.3;q32) and 17p13 in myeloma patients treated with high-dose therapy Clinical implications of t(11;14)(q13;q32), t(4;14) (p16.3;q32) and 17p13 in myeloma patients treated with high-dose therapy
113. 2005 A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS Blood 2005 Sep 15; 106(6):2156-61.
114. 2005 Genomics in multiple myeloma: biology and clinical implications Pharmacogenomics 2005 Sep; 6(6):563-73
115. 2005 Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol 2005 Sep 10; 23(26);6369-44
116. 2005 Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance J Clin Oncol 2005 Aug 20; 23(24):5668-74
117. 2005 Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005 Aug 10; 23(23):5347-56.
118. 2005 Genetics of multiple myeloma Baillieres Best PracRes Clin Haematol 2005; 18(4):525-536
119. 2005 Report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature Am J Hematol 2005 Apr; 78(4):288-94
120. 2005 Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis Blood 2005 Jan 15; 105(2):794-803
121. 2005 Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumoritenesis. Cancer Cell 2005 Jan; 7(1): 39-49
122. 2005 A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia 2005 Jan; 19(1):118-25
123. 2005 Use of the Serum Free Light Chain Assay in Assessment of Response to Therapy in Multiple Myeloma: Validation of Recently Proposed Response Criteria in a Prospective Clinical Trial of Lenalidomide Plus Dexamethasone for Newly Diagnosed Multiple Myeloma Blood 106 (Pt 1):971a, 2005
124. 2005 Low Level Amplification (Duplication) of 1q21 in Myeloma and Prognosis; the Role of CKS1B Blood 106 (Pt 1):185a, 2005.
125. 2005 Combination Therapy with Lenalidomide Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma Blood 106 (Pt 1):230a-321a, 2005
126. 2005 6q Deletion in Waldenström Macroglobulinemia Is the Most Common Cytogenetic Abnormality and Is Associated with Aggressive Disease with a Trend towards Worse Survival Blood 106 (Pt 1):290a, 2005
127. 2005 Gene Expression Profiling Identifies 4 Sub-Classes with Distinct Clinical Associations in Hyperdiploid Myeloma Blood 106 (Pt 1):441a, 2005
128. 2005 Gene Expression Profiling of Hyperdiploid Multiple Reveal Complex Gene Dosage Effects and an mRNA Translation/Protein Synthesis Signature Blood 106 (Pt 1):441a, 2005
129. 2005 Compendium of Karyotypic Abnormalities and Their Clinical Implications in Hyperdiploid Multiple Myeloma (H-MM). Blood 106 (Pt 1):442a, 2005
130. 2005 The t(4;14) Is Present in Patients with Early Stage Plasma Cell Proliferative Disorders Including MGUS and Smoldering Multiple Myeloma (SMM) Blood 106 (Pt 1):443a, 2005
131. 2005 One Half of Patients with Waldenström Macroglobulinemia Have Large Deletions of Chromosome 6q Blood 106 (Pt 1):444a, 2005
132. 2005 Comparison of Newly Diagnosed and Relapsed Refractory Multiple Myeloma Using Transcriptional Profiling of Myeloma Cells Blood 106 (Pt 1):446a, 2005
133. 2005 A Comparative Analysis of Chromosome 13 Gene Expression and Copy Number Changes in Multiple Myeloma Using Array-Based Methods Blood 106 (Pt 1):447a, 2005
134. 2005 A Phase II Study of PS-341 for Patients with High Risk, Newly Diagnosed Multiple Myeloma: A Trial of the Eastern Cooperative Oncology Group (E2A02). Blood 106 (Pt 1):715a, 2005
135. 2005 Genomic Analysis of High Hyperdiploid Acute Lymphoblastic Leukemia and Hyperdiploid Multiple Myeloma Suggests Differential Gene Dosage Effect on Expression and Provide Clues to Preferential Selection of Recurrently Trisomic Chromosomes Blood 106 (Pt 1):842a, 2005
136. 2005 Plasma Cells from Secondary Plasma Cell Leukemia Display Different Cytogenetics Pattern When Compared with Primary Plasma Cell Leukemia. Blood106 (Pt 1):913a, 2005
137. 2005 Cancer/Testis Antigen Profiling in Multiple Myeloma Define a Cohort of Patients with Poor Prognosis Regardless of Genetic Subtypes Blood 106 (Pt 1):945a, 2005
138. 2005 A Local Versus Centralized Processing Comparison of Plasma Cell Isolation, Viability, and RNA Integrity. Blood 106 (Pt 1):953a, 2005
139. 2005 Comparison of Myeloma Cell Gene Expression Profiles Pre and Post Thalidomide – Dexamethasone Therapy Provides Insight into Potential Mechanisms Blood 106 (Pt 1):971a-972a, 2005
140. 2005 Clinical Significance of the Tumor Suppressor p53 Codon 72 Polymorphic Variants in Multiple Myeloma Blood 106 (Pt 2):358b, 2005
141. 2005 Identification of Genes Associated with Increased Bone Marrow Angiogenesis in Multiple Myeloma Blood 106 (Pt 2):359b, 2005
142. 2005 Myeloma with t(11;14) and CD20+ Plasma Cells: Response to Rituximab Blood 106 (Pt 2):378b, 2005
143. 2005 Clinical implication of centrosome amplification in plasma cell neoplasm Blood 2005 Dec 22; 107:3669-75.
144. 2005 Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma Blood 2005 Dec 15; 106(13):4050-3.
145. 2005 Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial Haematologica 2005 Dec; 90(12):1650-1654
146. 2005 Risk stratification of patients with newly diagnosed multiple myeloma: optimizing treatment based on pretreatment characteristics Clinical Lymphoma & Myeloma 2005 Nov; 6(3):200-207.
147. 2005 Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma Blood 2005 Nov 15; 106(10):3553-8.
148. 2004 Waldenström’s macroglobulinemia Chapter 23, pp 411-28. Myeloma Biology and Management, 3rd Edition, JS Malpas, DE Bergsagel, RA Kyle, KC Anderson Eds. Saunders, Elsevier Inc., Philadelphia, 2004.
149. 2004 Cytogenetics of multiple myeloma Chapter 5, pp 67-81. Myeloma Biology and Management, 3rd Edition, JS Malpas, DE Bergsagel, RA Kyle, KC Anderson Eds. Saunders, Elsevier Inc., Philadelphia, 2004.
150. 2004 Prognostic factors and classification for multiple myeloma (contribution to clinical management). Chapter 11, pp 189-99. Myeloma Biology and Management, 3rd Edition, JS Malpas, DE Bergsagel, RA Kyle, KC Anderson Eds. Saunders, Elsevier Inc., Philadelphia, 2004.
151. 2003 Assays for neoplastic cell enrichment in bone marrow specimens Novel Anticancer Drug Protocols; Methods in Molecular Medicine series, vol. 85. JK Buolamwini, AA Adjei Ed. Humana Press, Chapter 26, pp 333-42, Totowa, NJ, 2003
152. 2003 Waldenström’s macroglobulinemia Wintrobe’s Clinical Hematology, 11th Edition. Lippincott, Williams & Wilkins. JP Gree Ed 2003
153. 2003 Many and multiple myeloma(s). Leukemia 2003;17:1943-4.
154. 2003 t(4;14)p16.3;132) is strongly associated with a shorter survival in myeloma patients. Br J Haematol 2003;120:170-1
155. 2003 Role of cytogenetics in myeloma. Myeloma: Biology and Management, 3rd Edition. Elseviere Science. J Malpas, DE Bergsagel, RA Kyle, K Anderson Eds 2003
156. 2003 Waldenström’s macroglobulinemia Handbook of Multiple Myeloma. Springer Verlog 2003
157. 2003 Plasma cell disorders; general considerations Wintrobe’s Clinical Hematology 11th Edition. Lippincott, Williams & Wilkins. JP Gree Ed 2003
158. 2003 Gamopatias Monoclonales; Clasificacion y gamopatia de significando incierto Hematologia. Ediciones Aran, Madrid, Spain. J San Miguel, J Garcia-Conde Eds 2003.
159. 2002 Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated puritus Blood 2002;99:2627
160. 2001 The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance Blood 2001;98:1271-2
161. 2001 Practical aspects in the diagnosis and management of aplastic anemia Practical aspects in the diagnosis and management of aplastic anemia
162. 2000 Testicular lymphoma is associated with a high risk of extranodal recurrence. Cancer 2000;89(3):714 [reply].
163. 2000 Multiple myeloma conn’s current therapy, pages 466-9, Robert E. Rakel and Edward T. Bope Ed. WB Saunders Company, Philadelphia, 2000
164. 1999 Ineffectiveness of pulmonary irradiation in the treatment of leukemic blast crisis Leukemia 1999;13(3):490
165. 1999 Prognosis in multiple myeloma diagnostic and therapeutic advances in hematologic malignancies, pages 155-170, Martin S. Tallman and Leo I. Gordon Ed. Kluwer Academic Publishers, Norwell, MA 1999
166. 1998 A descriptive study of chromosomal abnormalities in systemic amyloidosis and correlation with biologic/prognostic variables. Proceeds of the VII International Symposium on Amyloidosis, Parthenon Publishing, RA Kyle and MA Gertz Ed. New York 1998
167. 1998 Granulomatous vasculitis associated with herpes virus Mayo Clin Proc 1998;73(4);390-1
168. 1998 Creatinine kinase release after hepatic artery embolization in patients with carcinoid tumors. Creatinine kinase release after hepatic artery embolization in patients with carcinoid tumors.
169. 1996 Induction of adrenal suppression by megestrol acetate Ann Intern Medicine. 1996;124(6):613 [letter].
170. 1996 Megestrol acetate-induced adrenal suppression J Clin Oncol 1996;14(2);689


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.